Revolution Medicines' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.

The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.

UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.

Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.

UBS has a buy rating on the stock and a $175 price target.

Price: 163.98, Change: +0.99, Percent Change: +0.61